Figure 8.

Effects of LRAs on primary cells. A, effects of LRA treatments (100 ng/ml PMA + 1 μm ionomycin, or 10 μm prostratin, KA, or anthralin) on viability of CD4⁺ T cells from three uninfected donors after 24 h, as measured by ViaCount viability stain. B, effects of LRAs on total HIV RNA copies per million CD4⁺ T cells isolated from three cART-suppressed, HIV-infected donors. Empty circles indicate the limit of detection, where no viral RNA was observed. C, effects of LRA treatments on viability of PBMCs from six uninfected donors after 24 h, as measured by ViaCount viability stain. D, effects of LRAs on p24^Gag production in total cell lysate and cell culture supernatants of PBMCs from three additional cART-suppressed, HIV-infected donors. For each panel, shapes and/or colors denote individual donors.